Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-1 or hepatocyte growth factor can be involved in CAF-derived neovascularization in GC.
|
31281359 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
BAG3 may have an important role in HGF-mediated cell proliferation and metastasis in gastric cancer through an ERK and Egr1-dependent pathway.
|
30514177 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HGF and FAP expressions in 110 cases of GC, 130 cases of normal gastric mucosa and 115 cases of gastric ulcer were detected by streptavidin-perosidase (SP) method.
|
29134462 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
MACC1, HGF and c-Met might cooperatively participate in the malignant progression of gastric cancer.
|
29435059 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we characterized the inhibitory effect of HGF siRNA on tumor growth and angiogenesis in gastric cancer.
|
29285843 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our study found that the increased expression of HGF in CAFs induced by MET-unamplified GC contributed to the malignant phenotype of both MET-unamplified GC and CAFs in tumor microenvironment.
|
30158543 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is evident that hepatocyte growth factor (HGF) is clinically related to gastric cancer progression and metastasis.
|
29781036 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results showed that S100A11 is upregulated by HGF through the NF-κB pathway in gastric cancer and plays a role in cell proliferation and invasion in gastric cancer.
|
30662594 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, CAF‑derived HGF promotes angiogenesis, VM and mosaic vessel formation via PI3K/AKT and ERK1/2 signaling in gastric cancer and HGF may serve as a potential therapeutic target for cancer anti‑vascular treatment.
|
29917165 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher serum/plasma HGF levels are associated with therapy resistance and/or metastasis, while lower HGF levels are associated with progression-free survival and overall survival after treatment with targeted drugs in lung cancer, gastric cancer, colon cancer, and malignant melanoma.
|
28064454 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-26a/b could suppress tumor tumorigenesis and angiogenesis by targeting the HGF-VEGF axis and could serve as a potential treatment modality for targeted therapy in the clinical treatment of gastric cancer.
|
28738343 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
|
28314274 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, little is known about the relationship between miR-16 and HGF/c-Met in gastric cancer (GC).
|
27683052 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we report for the first time that HGF regulates HPA expression to promote gastric cancer metastasis.
|
25727320 |
2015 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, the clinical significance of the HGF/c‑Met pathway in the assessment of gastric cancer progression was evaluated.
|
25592281 |
2015 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy.
|
24663077 |
2014 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer.
|
23402812 |
2013 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to establish whether the HGF/c-Met pathway is associated with gastric cancer metastasis; especially peritoneal dissemination.
|
21796631 |
2012 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genes induced by hepatocyte growth factor (HGF) were screened using cDNA microarray technology in the stomach cancer cell lines, NUGC3 and MKN28.
|
21734448 |
2011 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
MET, the receptor for hepatocyte growth factor, has been proposed as a therapeutic target in gastric cancer.
|
21393565 |
2011 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
HGF regulates Rac-1-induced ROS production through the Akt pathway and ROS regulates uPA production and invasion via MAP kinase, which provides novel insight into the mechanisms underlying the progression of gastric cancer.
|
19497102 |
2009 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HGF and bFGF mRNA expression can be used as useful parameters to evaluate the prognosis of gastric cancer.
|
19533745 |
2009 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The majority of gastric cancers, i.e.76%, express c-MET and in all carcinomas HGF is expressed in either tumor or stromal cells.
|
15026993 |
2004 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates that 1) gastrin stimulates the gene and protein expression of COX-2 and HGF in human cultured gastric cancer cells and 2) gastrin shows antiapoptotic activity through the upregulation of Bcl-2 and survivin.
|
12674216 |
2003 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we evaluated HGF expression in both carcinoma cells and stromal cells in gastric cancers.
|
12381909 |
2002 |